Peri- and Post-Menopausal Hormone Replacement Therapy and Voice Disorder Risk: A TriNetX Study.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Peri- and Post-Menopausal Hormone Replacement Therapy and Voice Disorder Risk: A TriNetX Study.
Συγγραφείς:	Kayekjian D; Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.; University of Central Florida College of Medicine, Orlando, Florida, USA., Chun WB; Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA., Nguyen SA; Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA., O'Rourke AK; Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA., Meenan KD; Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Πηγή:	The Laryngoscope [Laryngoscope] 2026 Sep; Vol. 136 (9), pp. 3859-3865. Date of Electronic Publication: 2026 May 06.
Τύπος έκδοσης:	Journal Article
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8607378 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-4995 (Electronic) Linking ISSN: 0023852X NLM ISO Abbreviation: Laryngoscope Subsets: MEDLINE
Imprint Name(s):	Publication: <2009- >: Philadelphia, PA : Wiley-Blackwell Original Publication: St. Louis, Mo. : [s.n., 1896-
Ιατρικοί όροι (MeSH):	Voice Disorders/epidemiology , Voice Disorders/chemically induced , Hormone Replacement Therapy/adverse effects , Estrogen Replacement Therapy/adverse effects , Postmenopause* , Perimenopause*, Humans ; Female ; Middle Aged ; Retrospective Studies ; Adult ; Risk Factors ; Incidence
Περίληψη:	Objectives: The aim of this study was to elucidate the risk of developing voice disorders among peri- and post-menopausal female hormone replacement therapy (HRT) users. Methods: A retrospective cohort study was conducted using the TriNetX Global Collaborative Network. Females aged 40-60 years old were included and stratified into two cohorts: HRT users (n = 16,586) and HRT non-users (n = 248,725) while excluding for head and neck radiation/neoplasms, smoking, benign laryngeal lesions, thyroid disorders, gender dysphoria, and any other systemic hormone use. Voice and resonance disorders (VRD) and dysphonia were separately assessed at 3-month intervals post-HRT initiation after propensity score-matching for age, sex, race, and ethnicity. Odds ratios (ORs) with 95% confidence intervals (CIs) and risk differences (RD) were generated to compare outcomes. Results: HRT users had significantly higher odds of dysphonia, but not VRD, within 0-9 months (OR 1.72; 95% CI (1.01-2.95), OR 1.66; 95% CI (0.99-2.79), respectively). For HRT users with elevated BMI, the 1-year VRD incidence was not significantly different than non-HRT users (RD 0.19%, p = 0.069). Overall, the incidence of VRD and dysphonia within 1 year in both groups was < 0.5% and showed no significant difference at most times between groups. Conclusions: HRT may not have any significant clinical impact on the peri- and post-menopausal voice. Although higher odds were noted earlier after treatment, HRT users did not have higher odds of voice issues after 1 year. This study highlights the lack of consensus in literature and urges future research to fully understand the impact of HRT on peri- and post-menopausal voice. (© 2026 The Author(s). The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.)
References:	Obstet Gynecol. 2019 Jul;134(1):e1-e18. (PMID: 31241598) JAMA Otolaryngol Head Neck Surg. 2020 Nov 1;146(11):1045-1053. (PMID: 32790826) Facts Views Vis Obgyn. 2012;4(1):38-41. (PMID: 24753887) Maturitas. 1997 Sep;28(1):47-53. (PMID: 9391994) JAMA Intern Med. 2025 Nov 1;185(11):1330-1339. (PMID: 40952729) Fertil Steril. 2008 Nov;90(5 Suppl):S88-102. (PMID: 19007655) J Voice. 1999 Sep;13(3):424-46. (PMID: 10498059) Curr Opin Otolaryngol Head Neck Surg. 2010 Jun;18(3):171-5. (PMID: 20386449) Otolaryngol Head Neck Surg. 2018 Mar;158(3):409-426. (PMID: 29494316) Maturitas. 2015 May;81(1):88-92. (PMID: 25757366) J Clin Endocrinol Metab. 2015 Jun;100(6):2254-60. (PMID: 25875779) J Menopausal Med. 2020 Aug;26(2):69-98. (PMID: 32893509) JAMA Health Forum. 2024 Sep 6;5(9):e243128. (PMID: 39331372) J Voice. 2017 Jul;31(4):476-482. (PMID: 27989395) Menopause. 2022 Jul 1;29(7):767-794. (PMID: 35797481) J Voice. 2018 Jan;32(1):116-121. (PMID: 28359642) J Gen Intern Med. 2004 Jul;19(7):791-804. (PMID: 15209595) Nat Rev Dis Primers. 2015 Apr 23;1:15004. (PMID: 27188659) Menopause. 2026 Feb 01;33(2):232-241. (PMID: 40924880) Folia Phoniatr Logop. 2013;65(2):78-83. (PMID: 23948697) J Voice. 2012 Sep;26(5):671.e1-7. (PMID: 22578434) JAMA. 2026 Jan 13;335(2):117-118. (PMID: 41212720) JAMA. 2023 Feb 7;329(5):405-420. (PMID: 36749328) N Engl J Med. 2020 Jan 30;382(5):446-455. (PMID: 31995690) JAMA Intern Med. 2015 Apr;175(4):531-9. (PMID: 25686030) Laryngoscope. 2005 Nov;115(11):1988-95. (PMID: 16319611) Sleep Med Rev. 2020 Feb;49:101225. (PMID: 31739179) J Midlife Health. 2010 Jan;1(1):41-2. (PMID: 21799639) Laryngoscope. 2010 Oct;120(10):2022-32. (PMID: 20830762) JAMA. 2025 Oct 21;334(15):1318-1320. (PMID: 40971177) Laryngoscope. 2026 Sep;136(9):3859-3865. (PMID: 42092344) Ann Epidemiol. 2015 Oct;25(10):779-84.e1. (PMID: 26358364)
Contributed Indexing:	Keywords: dysphonia; hormone replacement therapy; peri‐menopause; post‐menopause
Entry Date(s):	Date Created: 20260507 Date Completed: 20260811 Latest Revision: 20260813
Update Code:	20260813
PubMed Central ID:	PMC13460510
DOI:	10.1002/lary.70612
PMID:	42092344
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	1531-4995
DOI:	10.1002/lary.70612